LoadingLoadingLoadingNo insider open-market trades in 90 days (SEC Form 4). Congress: both buying and selling, $3K to $45K in total in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and 1 fin-fluencer is discussing it.
Buys/Adds (1)
Alger
$235.3M
bought
Sells/Trims (2)
Two Sigma
$230.3M
trimmed
Susquehanna
$177.3M
trimmed
Buys (1)
Sells (2)
Top-trader positions in NVO could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.82 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$4.01 to $5.28
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $0.96 / $0.82Alpha Vantage | +17.07% beat | DKK 78.49B No estimate | Unavailable |
| Mar 31, 2026 | May 6, 2026 | $6.63 / $6.96Alpha Vantage | -4.74% miss | DKK 96.82B No estimate | Unavailable |
| Dec 31, 2025 | Feb 3, 2026 | $6.04 / $5.90Alpha Vantage | +2.37% beat | DKK 79.14B No estimate | Unavailable |
| Sep 30, 2025 | Nov 5, 2025 | $1.02 / $0.77Alpha Vantage | +32.47% beat | DKK 74.98B No estimate | Unavailable |
| Jun 30, 2025 | Aug 6, 2025 | $5.96 / $6.00Alpha Vantage | -0.67% in line | DKK 76.86B No estimate | Unavailable |
| Mar 31, 2025 | May 7, 2025 | $6.53 / $6.07Alpha Vantage | +7.58% beat | DKK 78.09B No estimate | Unavailable |
| Dec 31, 2024 | Feb 5, 2025 | $6.34 / $5.97Alpha Vantage | +6.20% beat | DKK 85.68B No estimate | Unavailable |
| Sep 30, 2024 | Nov 6, 2024 | $6.12 / $5.92Alpha Vantage | +3.38% beat | DKK 71.31B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
Fairly priced and profitable.
Valuation
Quality
Growth
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
NeutralOct 20Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
BullishOct 20Novo Nordisk said CagriSema was linked to 25% weight loss in women in new analysis
BullishOct 20Novo's CagriSema helped women lose 25% of weight on average, analysis shows
BullishOct 20Prediction: Eli Lilly Stock Could Be a Long-Term Winner for Investors
BearishOct 20Novo’s Former CEO Fruergaard Jorgensen to Join Lundbeck Board
NeutralOct 19Thousands of Novo Nordisk insulin pens stolen from Dutch wholesaler
Leans bearishOct 17Eli Lilly's weight-loss pill wins EU drug regulator's backing
Leans bullishOct 1632 macro signals shaping NVO right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results